Texas Children's Hospital

Other

The University of Texas System

Texas Heart Institute

Alzeca Biosciences, LLC

Sensulin, LLC

University of Houston System

Tanifum, Eric A.

Srivastava, Mayank

Annapragada, Ananth

Eric A Tanifum

Ananth V Annapragada

Mayank Srivastava

Indrani Dasgupta

Stephen C Cook

Jason Eriksen

Mostafa Analoui

Ketankumar B Ghaghada

Ronald J Biediger

James T Willerson

Robert V Market

Peter Vanderslice

Darren G Woodside

Carlo Medici

Anil Shetty

Xianwei Sun

Richard Dixon

Jason L Eriksen

Ananth Annapragada

A liposomal composition ('ADx-003') is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: wherein X is &#x2014;CH&#x2014;, &#x2014;CH&#x2014;CH&#x2014;, &#x2014;CHO&#x2014;, or &#x2014;O&#x2014;CO&#x2014;; Y is &#x2014;CH&#x2014;CH&#x2550;CH&#x2014; or A and B are independently selected from C and N; R, R, R, and Rare independently selected from &#x2014;H, halogen, &#x2014;OH, and &#x2014;CH; and R, R, and Rare independently selected from &#x2014;H, halogen, &#x2014;OH, &#x2014;OCH, &#x2014;NO, &#x2014;N(CH), C-Calkyl, or a substituted or unsubstituted C-Caryl group, except that when A and/or B is N the adjacent Rand/or Ris &#x2014;H, or a pharmaceutically acceptable salt thereof.

Targeted contrast agents for MRI of alpha-synuclein deposition

Disclosed herein is a composition comprising a plurality of liposomes having an average diameter of less than 400 nanometers, wherein the plurality of liposomes comprise: a first lipid or phospholipid; a second lipid or phospholipid which is derivatized with a polymer; and a sterically bulky excipient capable of stabilizing the liposomes; a third lipid or phospholipid derivatized with a polymer terminated with an integrin targeting component; DSPE or a fourth lipid or phospholipid derivatized with a group binding a contrast enhancing agent wherein the plurality of liposomes optionally encapsulates a payload component consisting of one or more bioactive agents.

Targeting nanoparticles

Readily available hydrophilic and small organofluorine moieties were condensed via 'click chemistry' to generate nonionic hydrophilic fluorinated molecules with uniqueF MR signatures. These were used to fabricate stable liposome formulations for imaging various tissue types. This approach was tailored to exploit the broad spectrum of organicF molecular species and to generate probes with distinctF MRI signatures for simultaneous assessment of multiple molecular targets within the same target volume.

Hydrophilic fluorinated molecules for liposomal 19F MRI probes with unique MR signatures

Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-&#x3b2; plaque deposits characteristic of Alzheimer's Disease.

MRI imaging of amyloid plaque using liposomes

A liposomal composition ('ADx-001') is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.

Targeted contrast agents for MRI of amyloid deposition

The present invention is directed towards new chemical entities based on a lipid-paramagnetic metal ion chelate. The lipid portion of the compound intercalates into the membrane of a liposome. The compounds of the invention find particular use as paramagnetic contrast media for magnetic resonance imaging. It has been surprisingly discovered that the liposomal contrast media do not substantially cross the placental barrier into the vasculature of the fetus(es) when administered to a pregnant subject. These novel compounds are useful in the diagnosis of disorders and diseases in both gravid and non-gravid subjects. The invention is also directed towards pharmaceutical compositions comprising these compounds and the uses of these compounds.

Liposomal gadolinium (GD) contrast agent 'NMRX' for T1-MRI

Lipid-based nanoparticle compositions are provided. The compositions generally comprise lipid-hydrophilic polymer-amyloid binding ligand conjugates, and may be liposomal compositions. The compositions, including the liposomal compositions, may be useful for imaging and/or the treatment of amyloid-&#x3b2; plaque deposits characteristic of Alzheimer's Disease.

Lipid-based nanoparticles

Vesicle compositions are provided that comprise a therapeutic compound. The vesicle compositions may be capable of releasing the therapeutic compound in response to the presence of an external trigger. The vesicle compositions may comprise a plurality of biocompatible vesicles. The biocompatible vesicles may comprise a therapeutic compound for treatment of a patient in need thereof, and one or more cross-linkages between two or more of the biocompatible vesicles, each cross-linkage comprising a chemical sensing moiety and a sensed moiety. In some embodiments, the therapeutic compound may be any compound that provides palliative, curative, or otherwise beneficial effects to a patent.

Vesicle compositions

Growing community of inventors

Katy, TX, United States of America

Eric A Tanifum